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Glycoprotein  (GP)  IIb/IIIa  inhibitors,  such  as  abciximab,  are  used  as  adjunctive  therapy  for  percutaneous  coronary 
intervention  (PCI)  in  high-risk  non-ST-elevation  myocardial  infarction  (NSTEMI)  and  in  ST-elevation  myocardial  infarction 
(STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more 
widespread, determining the risks associated with them becomes more important. The major risks associated with the 
use  of  GP  IIb/IIIa  inhibitors  are  the  potential  for  major  bleeding  and  thrombocytopenia.  This  is  the  first  reported  case 
in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly 
used  GP  Ilb/IIa  inhibitor,  following  PCI. 
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INTRODUCTION
The integrin GP IIb/IIIa receptor is the final common pathway 
for  platelet  aggregation.  Abciximab  is  an  anti-integrin  Fab 
fragment of a human-mouse chimeric monoclonal antibody with 
high  affinity  and  a slow  rate  of dissociation from the GP  IIb/IIIa 
platelet receptor
1). Intravenous glycoprotein (GP) IIb/IIIa inhibitors 
were  first  used  in  the  setting  of  PCI  in  an  attempt  to  reduce 
abrupt  vessel  closure  and  urgent  revascularization
1, 2).  Most 
cases  of  bleeding  associated  with  intravenous  glycoprotein 
inhibitors  have  occurred  in  patients  who  underwent  PCI,  and 
bleeding  primarily  occurred  at  the  femoral  artery  access  site
1).   
However, hemorrhagic pericarditis following the use of abciximab 
is  a  rare  event.  This  study  describes  a  case  of  cardiac 
tamponade  resulting  from  hemorrhagic  pericarditis  after  the  use 
o f  a b c i x i ma b  f o l l o w i n g  P C I  i n  a  p a t i e n t  w i t h  S T E MI .  
CASE REPORT
A  66-year-old  male  was  admitted  to  our  hospital  due  to 
ongoing  and  squeezing  chest  pain  accompanied  with  left 
shoulder  pain  that  had  most  recently  occurred  3  days  prior  to 
admittance. His past medical history included hypertension and a 
smoking  history  of  40  pack-years.  He  had  no  familial  history  of 
coronary  artery  or  cerebrovascular  disease,  and he  was not  on 
any  medication  at  the  time  of  admission.  Upon  physical 
examination his blood pressure was 130/90 mmHg and his heart 
rate was 64 beats per minute, with regular heart and normal S1 
and  S2  sounds.  Upon  auscultation,  his  breathing  sound  was 
clear.  The  initial  electrocardiography  indicated  ST  segment 
elevation  up  to  1.5  mm  in  lead  V5  and  V6  (Figure  1).  Initial 
Echocardiography  showed  akinesia  of  the  lateral  wall  from  the 
mid-ventricle  to  the  apex  in  the  left  ventricle  (LV).  Creatine 
phosphokinase (CPK), lactate dehydrogenase (LDH), CK-MB and 
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Figure  1.  ECG  taken  during  the  visit  to  the  emergency  room  showing  ST  segm e n t  e l e v a t i o n  u p  t o  1 . 5  m m  i n  l e a d  V 5  a n d  V 6 .  E C G  i n d i c a t e s  
electrocardiography.
 
Figure 2. Elective PCI performed 5 days after admission showing visible thrombus at the distal part of the left circumflex artery in the RAO caudal
v i e w  ( A ) .  T I M I  f l o w  o f  t h e  d i s t a l  l e f t  c i r c u m f l e x  a r t e r y  w a s  z e r o  a n d  a  v i s i b l e  t h r o m b u s  w a s  p r e s e n t  i n  t h e  m i d  p o r t i o n  ( B ) .  P CI  indicates 
percutaneous  coronary  intervention;  RAO,  right  anterior  oblique;  TIMI,  Thrombolysis  In  Myocardial  Infarction.
ng/mL,  respectively.  We  applied  conventional  heparin  initially 
(5000  unit  via  subcutaneous  injection)  followed  by  continuous 
infusion for 72 hours, subsequently targeting a prothrombin time 
( P T )  I N R  f r o m  1 . 5  t o  2 . 0 .  A d d i t i o n a l l y ,  w e  t r e a t e d  t h e  p a t i e n t  
daily  with  aspirin  (200  mg),  clopidogrel  (75  mg)  and  cilostazol 
(200 mg). After 5 days, we successfully performed elective PCI. 
Abciximab was applied during PCI because a visible thrombus at 
the  left  circumflex  coronary  artery  was  observed  during  the 
coronary  angiography  (Figure  2).  Abciximab  was  applied 
i n t r a v e n o u s l y  a t  1 0  m g  a n d  w a s  i n f u s e d  a t  1 0  ㎍ / m i n  f o r  1 2  
hours.  Vital  signs  were  stable  during  and  immediately  following 
PCI (Blood pressure 120/70 mmHg; heart rate 70 bpm) and the 
patient  did  not  complain  of  any  symptoms  such  as  chest 
discomfort  or  dyspnea.  The  electrocardiography  (ECG)  taken 
immediately following PCI showed no interval change compared 
with the previous ECG. Eleven hours after coronary intervention 
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Figure 3. ECG taken at the time of shock, which occurred 11 hours after PCI, showing ST segment elevation that 
progressed up to 3.0 mm in lead V5 and V6, and low voltage in limb leads. ECG indicates electrocardiography; PCI, 
percutaneous  coronary  intervention.
Figure 4. Emergent CAG performed for the purpose of ascertaining acute 
thrombus or coronary artery perforation, showing no evidence of these
events.  CAG  indicates  coronary  angiography.
the  patient  complained  of  chest  discomfort  and  dyspnea. 
Subsequently,  his  blood  pressure  decreased  to  60/30  mmHg 
and ST elevation in lead V5 and V6 increased to 3.0 mm (Figure 
3).  2nd  Echocardiography  after  the  PCI  showed  scanty 
pericardial  effusion  with  no  evidence  of  tamponade.  We 
conducted an emergent angiography to ascertain whether acute 
thrombus  after  PCI  or  coronary  perforation  had  occurred, 
however  the  angiography  showed  no  leakage  of  dye  or 
thrombus  in  any  coronary  arteries  (Figure  4).  Vital  signs  had 
remained  stable  and  the  patient  had  not  complained  of  any 
more  chest  discomfort.  Three  days  after  the  PCI,  the  patient 
complained  of  chest  discomfort  and  dyspnea,  and  shock 
occurred  again.  Echocardiography  after  the  shock  showed  a 
large  amount  of  pericardial  effusion,  which  confirmed  cardiac 
tamponade (Figure 5). Emergent pericardiocentesis was performed 
immediately  and  the  blood  pressure  soon  returned  to  normal. 
The  total  amount  of  bloody  pericardial  effusion  was 
approximately 950 cc. Following the initial effusion, neither chest 
pa i n  nor  a ny  s i gn of  s h oc k  de veloped.  Echocardiography  taken 
3  days  after  pericardiocentesis  showed  no  evidence  of 
pericardial effusion. The patient was discharged 6 days later and 
underwent follow up observation at an outpatient clinic and has 
remained well and free of any symptoms for more than 2 years. 
DISCUSSION 
Three  intravenous  GP  IIb/IIIa  inhibitors  (abciximab,  eptifibatide, 
and  tirofiban)  are  approved  for  treatment  in  the  United  States. 
Abciximab  (Reopro,  Centocor/Lilly),  the  first  GP  IIb/IIIa  inhibitor 
approved for clinical use, is a chimeric antibody directed against 
the  GP  IIb/IIIa  molecule.  Abciximab  acts  by  binding  to  the  GP 
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Figure  5.  Parasternal long axis  view (A)  and  apical  4-chamber view  (B) 
from  when  shock  occurred,  which  indicated  pericardial  effusion  had 
occurred  and  resulted  in  cardiac  tamponade.  PE  indicates  pericardial 
effusion;  LV,  left  ventricle.
(e.g.,  fibrinogen,  von  Willebrand  factor)  and  interfering  with 
platelet  aggregation.  Abciximab  is  currently  approved  for 
prevention  of  ischemic  complication  in  patients  undergoing  PCI 
and in patients with unstable angina when PCI is planned within 
24  hours
2).  Use  of  GP  IIb/IIIa  inhibitors  for  treating  NSTEMI 
p a t i e n t s  h a s  b e e n  a p p r o v e d  a n d  G P  I I b / I I I a  i n h i b i t o r s  a r e  
currently  being  used  to  reduce  postprocedural  ischemic 
complications  in  patients  undergoing  PCI. 
Despite  the  proven  effect  of  GB  IIb/IIIa  inhibitors  on  patients 
w i t h  N S T E M I  w h o  u n d e r g o  P C I ,  t h e i r  u s e  i s  a s s o c i a t e d  w i t h  
major or minor bleeding and thrombocytopenia, especially when 
abciximab is used
3). The risk of bleeding can be reduced by the 
use  of  low-dose  adjuctive  heparin,  early  sheath  removal,  and 
careful postprocedural care and attention to the vascular access 
s i t e .  M a j o r  v a s c u l a r  c o m p l i c a t i o n s  a f t e r  P C I  w h e n  G P  I I b / I I I a  
inhibitors  are  used,  such  as  psudoaneurysm,  arteriovenous 
fistula,  and  retroperitoneal  hematoma  reportedly  occur  in  0.5～
9%,  0.2～2.1%  and  0.15～0.44%  of  cases,  respectively
4). 
Although  abciximab  can  increase  the  possibility  of  bleeding 
complications  after  PCI,  as  occurred  in  this  case,  hemorrhagic 
pericarditis  leading  to  cardiac  tamponade  is  rare.  Additionally, 
cardiac  tamponade  associated  with  acute  myocardial  infarction 
or  PCI  is  a  rare  complication.  In  the  case  of  PCI,  pericardial 
effusion  that  causes  hemodynamic  compromise  is  usually  the 
result  of  hemorrhagic  pericarditis  and  it  is  reported  that 
anticoagulation therapy (use of heparin, aspirin, clopidogrel, etc.) 
clearly  increases  the  risk  for  hemorrhagic  pericarditis.  Cardiac 
tamponade  following  PCI  can  occur  due  to  a  guide  wire 
perforation  of  the  coronary  artery
5),  however,  in  our  case, 
emergent  angiography  showed  no  evidence  of  coronary  artery 
perforation.  Hemorrhagic  pericarditis  following  abciximab 
treatment  associated  with  PCI  was  demonstrated  by  echo-
cardiography,  suggesting  pericardial  effusion  and  coronary 
angiography,  which  in  turn  confirms  that  coronary  artery 
perforation did not occur. Therefore, we concluded that cardiac 
tamponade  was  caused  by  hemorrhagic  pericarditis,  which 
developed  as  a  complication  of  abciximab  treatment.
In conclusion, we reported a case of hemorrhagic pericarditis 
presenting  with  cardiac  tamponade  following  abciximab 
treatment  associated  with  PCI  in  a  patient  who  recently 
underwent  STEMI.  Further  clinical  trials  are  needed  to  evaluate 
and  prevent  probable  complications  associated  with  the 
increased use of  GP  IIb/IIIa inhibitors. It  is  particularly important 
t o  s t u d y  t h e  r e l a t i o n s h i p  b e t w e e n  h e p a r i n  a n d  G P  I I b / I I I a  
inhibitors.
REFERENCES
1) Gowda  RM,  Khan  IA,  Vasavada  BC,  Sacchi  TJ.  Therapeutics  of 
platelet  glycoprotein  IIb/IIIa receptor antagonism. Am J Ther 11:302- 
307,  2004
2) Midei MG, Coombs VJ, Lowry DR, Drossner MN, Prewitt KC, Wang 
JC,  Loughrey  MB,  Gottlieb  SO.  Clinical  outcomes  comparing 
eptifibatide and abciximab in ST elevation acute myocardial infarction 
patients  undergoing  percutaneous  coronary  intervention.  Cardiology 
107:172-177,  2006
3) Merlini  PA,  Rossi  M,  Menozzi  A,  Buratti  S,  Brennan  DM,  Moliterno 
DJ,  Topol  EJ,  Ardissino  D.  Thrombocytopenia  caused  by  abciximab 
o r  t i r o f i b a n  a n d  i t s  a s s o c i a t i o n  w i t h  c l i n i c a l  o u t c o m e  i n  p a t i e nts 
undergoing  coronary  stenting.  Circulation  109:2203-2206,  2004 
4) Konstance R, Tcheng JE, Wightman MB, Kelly LP, Moore A, Harrison 
JK,  Sketch  MH  Jr.  Incidence  and  predictors  of  major  vascular 







LVThe  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  3,  September  2008 160
glycoprotein  IIb/IIIa  platelet  inhibitor  era.  J  Interv  Cardiol  17:65-70, 
2004
5) van Mieghen C, Dens J, Herregods MC, Desmet W.  Left ventricular 
hematoma  and  cardiac  tamponade  complicating  percutaneous 
coronary  intervention  using  IIb/IIIa  receptor  antagonists.  J  Interv 
Cardiol  16:381-384,  2003